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Mouse cortical GABAergic synaptosomes possess presynaptic inhibitory GABAB
autoreceptors. Accordingly, (±)baclofen (3 µM) inhibits in a CGP53423-sensitive
manner the 12 mM KCl-evoked release of preloaded [3H]GABA. Differently, the
existence of presynaptic release-regulating metabotropic glutamate type 1 (mGlu1)
heteroreceptors in these terminals is still matter of discussion, although confocal
microscopy unveiled the existence of mGlu1α with GABAB1 or GABAB2 proteins in
cortical VGAT-positive synaptosomes. The group I mGlu agonist 3,5-DHPG failed
to modify on its own the 12 mM KCl-evoked [3H]GABA exocytosis from cortical
nerve endings, but, when added concomitantly to the GABAB agonist, it significantly
reduced the 3 µM (±)baclofen-induced inhibition of [3H]GABA exocytosis. Conversely,
the mGlu1 antagonist LY367385 (0.03–1 µM), inactive on its own on GABA
exocytosis, amplified the 3 µM (±)baclofen-induced inhibition of [3H]GABA overflow.
The ( ± )baclofen-induced inhibition of [3H]GABA exocytosis was more pronounced in
cortical synaptosomes from Grm1crv4/crv4 mice, which bear a spontaneous mutation of
the Grm1 gene leading to the functional inactivation of the mGlu1 receptor. Inasmuch,
the expression of GABAB2 receptor protein in cortical synaptosomal lysates from
Grm1crv4/crv4 mice was increased when compared to controls. Altogether, these
observations seem best interpreted by assuming that mGlu1 coexist with GABAB
receptors in GABAergic cortical synaptosomes, where they control GABA receptors
in an antagonist-like manner. We then asked whether the mGlu1-mediated control of
GABAB receptors is restricted to GABAergic terminals, or if it occurs also in other
subpopulations of nerve endings. Release-regulating GABAB receptors also exist in
glutamatergic nerve endings. (±)baclofen (1 µM) diminished the 12 mM KCl-evoked
[3H]D-aspartate overflow. Also in these terminals, the concomitant presence of 1 µM
LY367385, inactive on its own, significantly amplified the inhibitory effect exerted
by (±)baclofen on [3H]D-aspartate exocytosis. Confocal microscopy confirmed the
colocalization of mGlu1 with GABAB1 and GABAB2 labeling in vesicular glutamate type1
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transporter-positive particles. Our results support the conclusion that mGlu1 receptors
modulate in an antagonist-like manner presynaptic release-regulating GABAB receptors.
This receptor–receptor interaction could be neuroprotective in central disease typified by
hyperglutamatergicity.
Keywords: mGlu1 receptor, GABAB receptor, receptor–receptor interaction, Grm1crv4/crv4 mice, release
INTRODUCTION
Dimerization of G protein-coupled receptors (GPCRs) is a
necessity for signal transduction, leading from agonist binding
to G protein activation. Homodimers originate from the
association of two units of single receptor proteins, while
heterodimers involve different receptor proteins. Metabotropic
glutamate (mGlu) receptors exist as either homo or heterodimers
(Doumazane et al., 2010; Nicoletti et al., 2011), while GABAB
receptors are heterodimers (Pin and Bettler, 2016).
GABAB receptors have a widespread distribution in the central
nervous system (CNS) where they mediate the inhibition of
chemical transmission. They preferentially locate presynaptically,
close to the site of transmitter release, and contribute to
control synaptic plasticity. GABAB receptors exist as auto-
receptors on GABAergic nerve terminals (Pittaluga et al., 1987)
and as heteroreceptors on non-GABAergic terminals (i.e., the
glutamatergic and the peptidergic nerve endings, Bonanno and
Raiteri, 1993).
Release-regulating mGlu1 receptors also locate presynaptically
in CNS (Pittaluga, 2016) where they control glutamate (Musante
et al., 2008) noradrenaline (Longordo et al., 2006) and
acetylcholine (Feligioni et al., 2003) release. mGlu1 receptor
proteins are largely expressed in GABAergic interneurons. In
particular, evidence in the literature demonstrate that the mGlu1
receptor protein exists in GABAergic neurons in the cortex,
in the striatum, in the hippocampus and in the cerebellum
(Pellegrini-Giampietro, 2003; Ferraguti et al., 2008). The effects
that follow mGlu1 receptors activation/inactivation suggest
they could have a main role in controlling synaptic plasticity
(Battaglia et al., 2001; Pellegrini-Giampietro, 2003). Agonist
acting at mGlu1 receptors depress synaptic transmission in
the CA1 region of the rat hippocampus (Gereau and Conn,
1995; Morishita et al., 1998), while, in rat corticostriatal slices,
it inhibits GABA-mediated inhibitory postsynaptic currents
(Battaglia et al., 2001). Because of these actions, antagonists
acting at mGlu1 receptors are propose to be neuroprotective
(see for a review Pellegrini-Giampietro, 2003). Clear evidence
of the presynaptic release-regulating activity of mGlu1 receptors
in GABAergic nerve terminals, however, are so far incomplete
and deserve further investigation. 3,5-DHPG was reported to
increase the spontaneous GABA release from rat parietal-cortical
synaptosomes (Bragina et al., 2015), but it failed to affect the
release of GABA elicited by a mild depolarizing stimulus from
mouse cortical and hippocampal GABAergic nerve endings
(Musante et al., 2010; Rossi et al., 2013; Zucchini et al., 2013;
Pittaluga, 2016).
Evidence in the literature evidentiate that mGlu1 and GABAB
receptor proteins are co-expressed and physically associate in
selected CNS regions (Ige et al., 2000; Tabata et al., 2004;
Luján and Shigemoto, 2006; Rives et al., 2009; Tadavarty et al.,
2011). Furthermore, activation of GABAB receptors was shown
to increase calcium responses generated by mGlu1 receptors,
consistent with the functional cross-talk of the two GPCRs
(Hirono et al., 2001; Tabata et al., 2004). Conversely, whether
mGlu1 receptors could affect GABAB-mediated responses was
not so far investigated.
The present study aimed at confirming the existence of mGlu1
heteroreceptors in cortical GABAergic nerve endings, and,
concomitantly, at highlighting if these receptors could influence
the release-regulating activity of colocalized presynaptic GABAB
autoreceptors. Based on previous observations showing that
mGlu1 receptors could not modify on its own the depolarization-
evoked release of preloaded [3H]GABA, we posited that cortical
synaptosomes could represent an appropriate model to highlight
the mGlu1/GABAB receptor–receptor interaction. The working
hypothesis is that, if present in GABAergic nerve endings, the
activation of presynaptic mGlu1 receptors could elicit an intra-
terminal cascade of events insufficient “per se” to alter GABA
exocytosis, but sufficient to modulate intraterminal processes
which may affect the functions of other proteins, including
the GABAB subunits (Longordo et al., 2006). The study was
also extended to glutamatergic terminals to investigate whether
mGlu1 receptor modulates presynaptic release-regulating GABA
receptors also in non-GABAergic terminals.
MATERIALS AND METHODS
Animals
Mice (male, strain C57BL/6J) were obtained from Charles River
(Calco, Italy) and were housed in the animal facility of DIFAR,
Pharmacology and Toxicology Section, under environmentally
controlled conditions (temperature = 22◦C, humidity = 40%) on
a 12-h light/dark cycle with food and water ad libitum. Breeding
procedures were in accordance with the European legislation
(European Communities Council Directive of 24 November
1986, 86/609/EEC) and the ARRIVE guidelines.
Grm1crv4 mice with the spontaneous recessive crv4 mutation
were also used. The crv4 mutation occurred in the BALB/c/Pas
inbred strain and consisted of an intronic insertion of a
retrotransposon LTR (Long Terminal Repeat) fragment that
disrupted the Grm1 gene splicing, causing the absence of mGlu1
receptor protein. Grm1crv4/crv4 homozygous mice presented
mainly with motor coordination deficits and bone defects (Conti
et al., 2006; Musante et al., 2017). Affected (Grm1crv4/crv4) and
control [Grm1+/+, wild type (WT)] mice were maintained on the
same genetic background by intercrossing Grm1crv4/+ mice. The
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animals were housed at the animal facility of the IRCCS A.U.O.
San Martino-IST (Genoa, Italy). The procedures for breeding and
genotyping of Grm1crv4/crv4 mice were reviewed and approved
by the Animal welfare ethical committee of the IRCCS-AOU
San Martino-IST National Cancer Research Institute (Genoa,
Italy), and definitive approval obtained by the Italian Ministry of
Health (DDL 26/2014 and previous legislation; protocol number
371). To obtain the genotype of the mouse progeny, DNA was
extracted from ear clippings according to the manufacturer’s
protocol (KAPA Mouse Genotyping Kits). Crv4 mutation was
detected by DNA polymerase chain reaction (PCR) amplification
using specific primers as previously described (Musante et al.,
2010; Rossi et al., 2013).
All the mice were euthanized by cervical dislocation, followed
by decapitation, and the cortices were rapidly removed. The
experimental procedures were carried out at the animal facility
of DIFAR, Pharmacology and Toxicology Section, and approved
by the Italian Ministry of Health (DDL 26/2014 and previous
legislation; protocol number 02/10/06/2015-OPBA), according
to the Guidelines for Animal Care and Use of the National
Institutes of Health and according to the Society’s Policies on
the Use of Animals and Humans in Neuroscience Research. In
line with the 3Rs rules (replacement, refinement, and reduction),
any effort was made to reduce the number of animals to obtain
statistically reliable results. All experiments were performed using
adult animals (3–8 months of age).
Preparation of Synaptosomes
Mouse cortical purified synaptosomes were prepared as
previously described (Summa et al., 2013). Briefly, the mouse
cortex was homogenized in 10 volumes of 0.32 M sucrose,
buffered to pH 7.4 with Tris-(hydroxymethyl)-amino methane
(TRIS, final concentration 0.01 M) with a glass/Teflon tissue
grinder (clearance 0.25 mm). The homogenate was centrifuged
(1000 x g for 5 min) to remove nuclei and debris, and the
supernatant was gently layered on a discontinuous Percoll
gradient (6, 10, and 20% v/v in Tris-buffered sucrose). After
centrifugation at 33,500 x g for 5 min, he layer between 10 and
20% Percoll (synaptosomal fraction) was collected and washed
by centrifugation (20,000 × g for 16 min). Synaptosomes were
resuspended in a physiological medium having the following
composition (mM): NaCl, 140; KCl, 3; MgSO4, 1.2; CaCl2, 1.2;
NaH2PO4, 1.2; NaHCO3, 5; HEPES, 10; glucose, 10; pH 7.4.
Release Experiments
Synaptosomes were incubated for 15 min at 37◦C in a rotary
water bath in the presence of [3H]GABA (f.c: 20 nM) or [3H]D-
aspartate ([3H]D-Asp, f.c.: 50 nM). Fifty micrometer amino-
oxyacetic acid was added during the incubation to avoid GABA
catabolism. Identical portions of the synaptosomal suspension
were then layered on microporous filters at the bottom of
parallel thermostated chambers of a Superfusion System (Raiteri
et al., 1974; Pittaluga, 2016; Ugo Basile, Comerio, Varese,
Italy). Synaptosomes were then superfused at 0.5 ml/min with
physiological medium. Synaptosomes were equilibrated during
36 min of superfusion and starting from t = 36 min superfusate
fractions were collected as follows to quantify tritium release:
two 3-min samples (basal release), one before (t = 36–39) and
one after (t = 45–48 min) a 6-min fraction (t = 39–45 min;
evoked release). Synaptosomes were exposed for 90 s, starting
from t = 39 min, to high KCl solution (12 mM, NaCl substituting
for an equimolar concentration of KCl, Zucchini et al., 2013), in
the absence or in the presence of GABAB receptor and/or mGlu1
receptor agonists and antagonists, as well as protein kinase C
(PKC) inhibitor.
The amount of radioactivity released into each superfusate
fraction was expressed as percentage of the total synaptosomal
radioactivity. The 12 mM KCl -evoked tritium overflow was
evaluated by subtracting the neurotransmitter content in the first
and in the third fractions collected (basal release, b1 and b3)
from that in the 6-min fraction collected during and after the
depolarization pulse (evoked release, b2). In all the figures, data
are reported as the mean ± SEM of independent determinations
obtained in different experiments run in triplicate (at least three
superfusion chambers for each experimental condition).
Confocal Microscopy and Colocalization
Mouse cortical synaptosomes were fixed with 2%
paraformaldehyde, permeabilized with 0.05% Triton X-100
phosphate-buffered saline (PBS) and incubated overnight
at 4◦C with the following primary antibodies diluted in 3%
albumin PBS: rabbit anti-mGlu1a (1:500), mouse anti-GABAB1
(1:500), mouse anti-GABAB2 (1:500), guinea pig anti-vesicular
GABA transporter (VGAT, 1:300), and guinea pig anti-vesicular
glutamate transporter type 1 (VGLUT1; 1:500) as indicated.
Synaptosomes were then washed in PBS and incubated for 1 h
at room temperature with the following secondary antibodies:
donkey anti-mouse AlexaFluor-647, goat anti-guinea pig
AlexaFluor-488, goat anti-rabbit AlexaFluor-555 as appropriate.
Finally, synaptosomes were applied onto coverslips (Musante
et al., 2008). Fluorescence images (512 × 512 pixels) were
acquired by a Leica TCS SP5 confocal microscope, through a
63X/1.4 NA objective. Bleed-through of emission spectra was
avoided by sequential channel acquisition. The evaluation of
colocalized proteins was performed as previously described
(Summa et al., 2013), by using the “Colocalization threshold”
plugins (WCIF Colocalization Plugins, Wright Cell Imaging
Facility, Toronto Western Research Institute, Canada) in the
ImageJ 1.51w software (Wayne Rasband, NIH, Bethesda, MD,
United States).
Immunoblot Analysis
Cortical synaptosomes from Grm1crv4/crv4 and WT mice of
the same breeding and age were homogenized in lysis buffer
[10 mM Tris, pH 8.8, 20% glycerol, 2% sodium dodecyl
sulfate (SDS), 0.1 mM Ethylenediaminetetraacetic acid (EDTA),
5% β-mercaptoethanol]. The protein concentration of the
homogenates was determined using the Bradford method.
Twenty microgram of total protein was separated on a
4–15% precast polyacrylamide gel (Bio-Rad) by means of
SDS–polyacrylamide gel electrophoresis. The concentration of
proteins in each sample was on the linear portion of the curve.
A triplicate analysis was performed for each lysate sample.
Electroblotted proteins were monitored using Naphtol blue black
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FIGURE 1 | Identification and colocalization (white, D and H, merge) of GABAB1 and of GABAB2 and of mGlu1 receptor proteins and vesicular GABA transporter
(VGAT) in mouse cortical synaptosomal particles. GABAergic synaptosomes were identified as VGAT-immunopositive particles (blue, panels A and E) and they were
analyzed for the GABAB1 receptor protein content (red, panel C), for the GABAB2 receptor protein content (red, panel G) and for the mGlu1α receptor protein
content (green, panels B and F). The figure shows representative images of five independent experiments carried out in different days.
staining. Membranes were then incubated with the following
antibodies: mouse monoclonal anti-mGlu1 receptor antibody
(1:2500); mouse monoclonal anti-GABAB1 receptor antibody
(1:500); mouse monoclonal anti-GABAB2 receptor antibody
(1:500); mouse monoclonal anti-Gapdh antibody (1:10000).
After incubation with peroxidase-coupled secondary antibodies,
protein bands were detected by using a Western blotting
detection system (ECL AdvanceTM). Bands were detected and
analyzed for density using an enhanced chemiluminescence
system (Versa-Doc 4000; Bio-Rad), and QuantityOne software
(Bio-Rad). All of the protein bands used were normalized for
Gapdh level in the same membrane.
Statistical Analysis
For data handling/statistics and for graph drawing Sigma plot 10
data analysis and graphing software package was used. Analysis
of variance was performed by ANOVA, followed by Dunnett’s
or Tukey’s multiple-comparisons test; direct comparisons were
performed by Student’s t-test or by Mann Whitney test, as
indicated. The level of significance was set at p < 0.05.
Chemicals
[2,3-3H]D-aspartate (specific activity 11.3 Ci/mmol) and
[3H]GABA (specific activity 30.0 Ci/mmol) were from
Perkin Elmer (Boston, MA, United States). (±)-baclofen,
LY367385, (RS)-3,5 DHPG, and CGP 52432 were purchased
from Tocris Bioscience (Bristol, United Kingdom). GF109203X,
aminooxyacetic acid, naphtol blue black staining, horseradish
peroxidase-coupled anti-mouse and anti-rabbit secondary
antibodies were from Sigma (Milan, Italy). Donkey anti-mouse
AlexaFluor-647, goat anti-guinea pig AlexaFluor-488, goat anti-
rabbit AlexaFluor-555 were from Life Technologies Corporation
(Carlsbad, CA, United States). Mouse anti-GABAB1 and mouse
anti-GABAB2 antibodies were from Santa Cruz Biotechnology
(Dallas, TX, United States). Rabbit anti-mGlu1 antibody,
used in confocal analysis, was from Abcam (Cambridge,
United Kingdom) and mouse anti-mGlu1 monoclonal antibody,
used in Western blotting, was from BD Biosciences (San
Jose, CA, United States). Guinea pig anti-vesicular glutamate
transporters type 1 antibody was from Millipore (Temecula, CA,
United States). Guinea pig anti-VGAT was from AlomoneLabs
(Jerusalem, Israel). Bradford assay was from Bio-Rad (Segrate,
Milan, Italy). KAPA Mouse Genotyping Kits were from Kapa
Biosystems (Woburn, MA, United States). ECL AdvanceTM was
from Amersham Biosciences (Piscataway, NJ, United States).
RESULTS
Mouse Cortical GABAergic Nerve
Endings Possess mGlu1, GABAB1, and
GABAB2 Receptor Proteins
We performed confocal analysis to detect the presence of
mGlu1α, GABAB1, and GABAB2 immunopositivity in purified
cortical synaptosomes that express the VGAT protein, here
used as a selective marker of GABAergic particles. We
identified a large colocalization (93 ± 3%) of GABAB1
(red, Figure 1C) or of GABAB2 (89 ± 2%) immunostaining
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(Figure 1G, red) with VGAT in hippocampal particles (blue,
Figures 1A,E, respectively). Furthermore, VGAT-positive
cortical synaptosomes (blue, Figures 1A,E, respectively)
efficiently stained for mGlu1α receptor protein (green,
Figures 1B,F, 66 ± 3%). Finally, we analyzed the colocalization
of mGlu1α receptor protein (green, Figures 1B,F) with GABAB1
and GABAB2 subunits (red, Figures 1C,G, respectively).
A diffuse colocalization of mGlu1α immune-positivity with
GABAB1 and with GABAB2 subunit proteins was observed. The
impossibility to perform a triple-labeling quantification,
however, does not allow speculating the percentage of
colocalization of the mGlu1 and GABAB receptor proteins
in the GABAergic synaptosomal particles, although there is a
high overlapping of the mGlu1α with either the GABAB1 and




Heteroreceptors Functionally Interact in
Mouse Cortical GABAergic Nerve
Endings
Presynaptic release-regulating GABAB autoreceptors exist in
both rat (Pittaluga et al., 1987) and mouse (Lin et al., 1995)
cortical synaptosomes. The activation of these receptors hampers
the [3H]GABA exocytosis elicited by 12 mM KCl. Accordingly,
3 µM (±)baclofen significantly reduced the 12 mM KCl-
evoked overflow of preloaded [3H]GABA from superfused
mouse cortical synaptosomes (Bonanno et al., 1997). The
(±)baclofen-induced effect was prevented by 0.1 µM of the
GABAB antagonist CGP52342 (12 mM KCl/3 µM (±)baclofen:
68.67 ± 3.47%; 12 mM KCl/3 µM (±)baclofen/0.1 µM
CGP52342: 95.45± 4.56%, result expressed as percent of residual
exocytosis, n = 5, p < 0.05, see also Raiteri, 2008). CGP52342
alone did not modify the KCl-evoked release of [3H]GABA from
cortical synaptosomes (not shown).
Figure 2 shows that the broad spectrum group I agonist 3,5-
DHPG (30 µM, i.e., a drug concentration able to fully activate
mGlu1 receptor subtypes, Musante et al., 2008) does not affect
the 12 mM KCl-evoked release of the radiolabelled transmitter
from cortical synaptosomes.
We asked whether activating or inactivating mGlu1 ligands
could modulate the release-regulating activity of presynaptic
GABAB autoreceptors. To this aim, experiments were carried
out to quantify the impact of the mGlu1 receptor agonist 3,5-
DHPG on the (±)baclofen-induced inhibition of [3H]GABA
exocytosis. The mGlu1 agonist slightly, although significantly,
reduced the 3 µM (±)baclofen-induced inhibition of the 12 mM
KCl-evoked [3H]GABA overflow from superfused mouse cortical
synaptosomes (Figure 2). Conversely, the mGlu1 antagonist
LY367385 (0.03–1 µM) significantly amplified the inhibitory
effect exerted by 3 µM (±)baclofen on the 12 mM KCl-evoked
exocytosis of [3H]GABA. At the maximal concentration applied,
the mGlu1 antagonist failed to affect on its own the release of
tritium evoked by high KCl (Figure 3).
Impact of Grm1 Mutation on the GABAB
Autoreceptors Controlling GABA Release
in Mouse Cortical GABAergic Nerve
Endings
We then examined the 12 mM KCl-evoked overflow of
preloaded [3H]GABA and its modulation by presynaptic release-
regulating GABAB autoreceptors in cortical synaptosomes
from Grm1crv4/crv4 mice, the mouse mutants bearing a genetic
mutation that inactivate the mGlu1 receptor coding gene
(Gmr1, Conti et al., 2006; Bossi et al., 2018). The release of
[3H]GABA elicited by the mild depolarizing stimulus was
not affected by the genetic mutation (WT mice, 12 mM
KCl-evoked [3H]GABA overflow: 5.19 ± 0.53, n = 6;
Grm1crv4/crv4 mice, 12 mM KCl-evoked [3H]GABA outflow:
5.13 ± 0.48, n = 6; n.s.; data expressed as KCl-evoked tritium
overflow).
Differently the inhibition of the [3H]GABA exocytosis elicited
by (±)baclofen (1–10 µM) was significantly reinforced in
Grm1crv4/crv4 mouse cortical synaptosomes when compared to
w.t. mice (Figure 4).
Impact of the Grm1 Mutation crv4 on the
GABAB1 and GABAB2 Receptor Proteins
Expression in Mouse Cortical Nerve
Endings
According to results obtained from release experiments, an
altered expression of GABAB1 receptor, GABAB2 receptor
or both could account for functional changes in GABAB-
mediated control of GABA exocytosis. Thus, we quantified
the amount of GABAB1 and GABAB2 subunit proteins in
cortical synaptosomes isolated from Grm1crv4/crv4 and WT
mice. Figure 5 shows that the Grm1 inactivating mutation
did not cause a significant change in the GABAB1 subunit
content when compared to WT mice. Differently, a significant
enhancement of the amount of GABAB2 subunit was observed
in Grm1crv4/crv4 mice lacking mGlu1 receptors when compared
to WT mice.
PKC-Dependent Intraterminal Pathway
Links mGlu1 and GABAB Receptors in
Mouse Cortical GABAergic Nerve
Endings
GABAB receptors desensitize and desensitization often occurs
because of an enhanced phosphorylation of the GABAB proteins
themselves. In particular, PKC activity attenuates the release-
regulating activity of GABAB receptors by promoting receptor
desensitization, through the phosphorylation of the GABAB1
subunits and the dissociation from the N-ethylmaleimide-
sensitive fusion (NSF) protein (Terunuma et al., 2010 and
references therein). Activation of mGlu1 receptors triggers PKC-
dependent phosphorylative pathways. We asked whether the
mGlu1-mediated modulation of the GABAB-induced inhibition
of GABA release relies on PKC-mediated events. To this aim,
synaptosomes were exposed to GF109203X (0.1 µM), a PKC
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FIGURE 2 | Presynaptic release-regulating GABAB autoreceptors and mGlu1 heteroreceptors functionally cooperate to control GABA exocytosis from mouse
cortical GABAergic nerve endings. Effects of 3 µM (±)baclofen and 30 µM 3,5-DHPG alone or concomitantly added on the 12 mM KCl-induced [3H]GABA overflow
from mouse cortical nerve terminals. Results are expressed as percentage of the 12 mM KCl-induced [3H]GABA overflow (percent of residual). Data are the
means ± SEM of five experiments run in triplicate. ∗∗∗p < 0.001 versus the 12 mM KCl-induced tritium overflow;
◦ ◦ ◦
p < 0.001 versus the 12 mM KCl/30 µM
3,5-DHPG-induced tritium overflow; § p < 0.05 versus the 12 mM KCl/3 µM (±)baclofen-induced tritium overflow.
FIGURE 3 | The mGlu1 receptor antagonist LY367385 favors the GABAB autoreceptor-mediated control of preloaded [3H]GABA from mouse cortical GABAergic
nerve endings. Effect of 3 µM (±)baclofen in the absence or in the presence of LY367385 (0.03–1 µM) on the release of preloaded [3H]GABA elicited by 12 mM KCl.
Results are expressed as percentage of the 12 mM KCl-induced [3H]GABA overflow (percent of residual). Data are the means ± SEM of seven experiments run in
triplicate. ◦p < 0.05 versus the 12 mM KCl-induced tritium overflow; ◦◦◦p < 0.001 versus the 12 mM KCl-induced tritium overflow; ∗p < 0.05 versus the 12 mM
KCl/3 µM (±)baclofen-induced tritium overflow; ∗∗p < 0.01 versus the 12 mM KCl/3 µM (±)baclofen-induced tritium overflow.
selective blocker, and the impact of 3 µM (±)baclofen on
the 12 mM KCl-evoked [3H]GABA overflow was analyzed.
Figure 6 shows that the concomitant presence of the PKC
inhibitor caused a huge significant reinforcement of the
3 µM (±)baclofen-induced inhibition of tritium overflow
when compared to control condition. The PKC blocker failed




Autoreceptors Functionally Interact in
Mouse Cortical Glutamatergic Nerve
Endings
We asked whether the mGlu1-GABAB receptor–receptor
interaction is restricted to the GABAergic nerve endings or,
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FIGURE 4 | The mGlu1 genetic mutation affect the release-regulating activity of presynaptic GABAB autoreceptors controlling [3H]GABA exocytosis from cortical
GABAergic nerve endings. Synaptosomes from the cortices of control (WT, white bar) animals and of Grm1crv4/crv4 mice (gray bar) were exposed to 12 mM KCl in
the absence or in the presence of (±)baclofen (1–10 µM). Results are expressed as percentage of the 12 mM KCl-induced [3H]GABA overflow (percent of residual).
Data are the media ± SEM of five experiments run in triplicate (three superfusion chambers for each mouse strain). ∗p < 0.05 versus the 12 mM KCl-evoked tritium
overflow from WT cortical synaptosomes; +p < 0.05 versus the 12 mM KCl-evoked tritium overflow from Grm1crv4/crv4 cortical synaptosomes; ++p < 0.01 versus
the 12 mM KCl-evoked tritium overflow from Grm1crv4/crv4 cortical synaptosomes; ◦p < 0.05 versus the 12 mM KCl/1 µM (±)baclofen-evoked tritium overflow from
w.t. cortical synaptosomes; ˆ ˆ p < 0.01 versus the 12 mM KCl/10 µM (±)baclofen-evoked tritium overflow from w.t. cortical synaptosomes.
FIGURE 5 | Expression of GABAB2 receptor proteins is significantly increased in cortical synaptosomes of Grm1crv4/crv4 mice. Western blotting analyses were
performed to determine the levels of GABAB1 and GABAB2 receptor expression in cortical synaptosomes (n = 4) of Grm1crv4/crv4, and age-matched WT mice.
(A) Examples of immunoreactive bands obtained from cortical synaptosomes (20 µg proteins/lane) from WT and mutated mice. (B) Quantification of GABAB1 and
GABAB2 receptor expression in cortical synaptosomes. The relative expression level of GABAB1 and GABAB2 receptor is expressed as the ratio of GABAB1 and
GABAB2 receptor to the glyceraldeide-3-phosphate dehydrogenase (Gapdh) protein. Data represent the mean ± SEM (percentage versus WT mice). ∗p < 0.05
versus WT cortical synaptosomes.
alternatively, if it also occurs in other subpopulations of nerve
endings. Presynaptic release-regulating GABAB heteroreceptors
exist in cortical glutamatergic terminals. By acting at these
receptors, (±)baclofen, inhibits significantly the 12 mM KCl-
induced [3H]D-Aspartate ([3H]D-Asp) exocytosis (Raiteri,
2008). Accordingly, 1 µM (±)baclofen significantly reduced the
12 mM KCl-evoked overflow of preloaded [3H]D-Asp (Figure 7).
Furthermore, these terminals also possess mGlu1 autoreceptors,
whose activation potentiates the 12 mM KCl-evoked release
of [3H]D-Asp (Musante et al., 2008). Figure 7 shows that,
when concomitantly added to 1 µM (±)baclofen, LY367385
(0.1 µM) significantly reinforced the inhibitory effect exerted
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FIGURE 6 | The release-regulating activity of presynaptic GABAB autoreceptors in cortical GABAergic nerve endings depends on PKC-mediated intraterminal
processes. Effects of the PKC inhibitor GF109203X (0.1 µM) on the 12 mM KCl in the absence or in the presence of 3 µM (±)baclofen. Results are expressed as
percentage of the 12 mM KCl-induced [3H]GABA overflow (percent of residual). Data are the means ± SEM of four experiments run in triplicate. ∗p < 0.05 versus
the 12 mM KCl-induced tritium overflow; ++p < 0.01 versus the 12 mM KCl/0.1 µM GF109203X- induced tritium overflow;
◦
p < 0.05 versus the 12 mM KCl/3 µM
(±)baclofen-induced tritium overflow.
FIGURE 7 | The mGlu1 receptor antagonist LY367385 amplifies the GABAB heteroreceptor-mediated control of [3H]D-aspartate release from glutamatergic mouse
cortical nerve endings. Effect of 1 µM (±)baclofen in the absence or in the presence of LY367385 (0.1 µM) on the release of preloaded [3H]D-aspartate ([3H]D-Asp)
elicited by 12 mM KCl. Results are expressed as percentage of the 12 mM KCl-induced [3H]D-Asp overflow (percent of residual). Data are the means ± SEM of five
experiments run in triplicate. ∗∗p < 0.01 versus the 12 mM KCl-induced tritium overflow; ∗∗∗p < 0.001 versus the 12 mM KCl-induced tritium overflow;
◦◦◦p < 0.001 versus the 12 mM KCl/0.1 µM LY367385-induced tritium overflow; ˆp < 0.05 versus the 12 mM KCl/1 µM (±)baclofen-induced tritium overflow.
by the GABAB agonist on the 12 mM KCl-evoked overflow of
preloaded [3H]D-Asp. At the concentration applied LY367385
did not modify the release of tritium evoked by high KCl (see
also Musante et al., 2008).
mGlu1, GABAB1, and GABAB2 Receptor
Proteins Colocalize in Mouse Cortical
Glutamatergic Nerve Endings
Confocal microscopy was also performed by labeling cortical
synaptosomes with VGLUT1 antibody (blue, Figures 8A,E),
to highlight glutamatergic nerve endings, and with anti-
mGlu1α antibody (green, Figures 8B,F) and with antibodies
recognizing the GABAB1 (red, Figure 8C) and the GABAB2
(green, Figure 8G) receptor proteins. Synaptosomal preparations
efficiently stained for all the antibodies tested and the
colocalizations of VGLUT1 and mGlu1α receptor proteins,
of VGLUT1 and GABAB1 receptor proteins and of VGLUT1
and GABAB2 receptor protein were analyzed. Merging of the
appropriate image pairs revealed that a large percentage of
VGLUT1-positive particles expressed mGlu1 receptor proteins
(46 ± 7%), as well as GABAB1 (52 ± 7%) and GABAB2
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FIGURE 8 | Identification and colocalization (white, D and H, merge) of GABAB1, of GABAB2 and of mGlu1 receptor proteins and of VGLUT1 in mouse cortical
synaptosomal particles. Glutamatergic synaptosomes were identified as VGLUT1-immunopositive particles (blue, panels A and E) and they were analyzed for the
GABAB1 receptor protein content (red, panel C), for the GABAB2 receptor protein content (red, panel G) and for the mGlu1 receptor protein content (green, panels B
and F). The figure shows representative images of four independent experiments carried out in different days.
(45 ± 6%) receptor subunits. Confocal analysis also unveiled a
colocalization of mGlu1α staining with GABAB1 and GABAB2
immuno-positivities. Again, the triple-labeling quantification of
the percentage of colocalization of the mGlu1 and GABAB
receptor proteins in the glutamatergic synaptosomes cannot be
proposed. However, the merged images (Figures 8D,H, merge,
white) indicates a high overlapping of the mGlu1α with either
the GABAB1 and GABAB2 stainings in the VGLUT1-positive
particles.
DISCUSSION
The existence and the role of mGlu1 receptors controlling
presynaptically the release of GABA has been argument of
discussion for several years. GABAergic interneurons were
proposed to possess mGlu1 receptors the activation of which
alters inhibitory transmission, also at GABAergic autapses. This
conclusion was also supported by the observations that mGlu1
antagonists are neuroprotectant and that neuroprotection is
abolished by increasing the [GABA]out by means of GABA
uptake inhibitors (Baude et al., 1993; Gereau and Conn, 1995;
Morishita et al., 1998; Battaglia et al., 2001). Most of these studies,
however, failed to prove the existence of presynaptic release-
regulating mGlu1 receptors in GABAergic nerve endings. Rather,
some of them proposed the existence of postsynaptic mGlu1
receptors promoting the endogenous production of cannabinoids
that retrogradally modulate GABA release (Alger, 2002; Diana
et al., 2002; Gerdeman et al., 2002; Pellegrini-Giampietro, 2003;
Ferraguti et al., 2008). The complexity of the scenario is now
further implemented by our results which suggest the existence
of presynaptic mGlu1 receptors coupled in an “antagonist-like
manner” to presynaptic GABAB receptors.
Neurotransmitters are usually analyzed individually, for their
releasing activity, unmindful that they also trigger receptor-
mediated events that control the function(s) of other, by-
standing, receptors. The complexity that originates from these
converging actions is referred to as “metamodulation” and
have a huge impact on synaptic transmission in CNS (Marchi
et al., 2015). A useful approach to study “metamodulation”
is the technique of the “up-down superfusion of a thin layer
of synaptosomes” (Raiteri et al., 1974; Raiteri and Raiteri,
2000; Pittaluga, 2016). By assuring the rapid removal of any
substances endogenously released, this technique prevents the
presence of the biophase, then impeding the onset of indirect
events due to endogenous compounds acting at presynaptic
receptors (including those produced postsynaptically, i.e.,
the endocannabinoids). This approach represents therefore a
method of choice to highlight the functional cross-talk linking
presynaptic receptors (Pittaluga et al., 2000, 2005; Musante
et al., 2011; Summa et al., 2011; Grilli et al., 2012; Di Prisco
et al., 2016). By a functional point of view, the receptor–
receptor interaction can be evidentiated in release studies
as change(s) in transmitter release efficiency observed when
exposing concomitantly synaptosomes to exogenous ligands
acting at the colocalized receptors (Longordo et al., 2006; Luccini
et al., 2007; Olivero et al., 2018). In general, it is proposed that
two receptors coexist and functional couple when the releasing
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activity due to their concomitant activations differs quantitatively
from the sum of the releasing effects elicited by each receptor
(Pittaluga and Raiteri, 1992).
The fact that mGlu1 ligands cannot modify GABA exocytosis
(Pittaluga and Raiteri, 1992; Musante et al., 2010; Zucchini
et al., 2013) hugely simplifies the system and led us to propose
the cortical GABAergic terminals as an appropriate model to
investigate the consequences of the mGlu1/GABAB receptor–
receptor interaction. In release studies, we confirmed that neither
3,5-DHPG nor LY367385 caused changes to GABA exocytosis.
The two ligands, however, significantly influenced the control of
GABA exocytosis elicited by presynaptic GABAB autoreceptors.
In particular, the mGlu1 agonist significantly reduced the
(±)baclofen-mediated inhibition of GABA exocytosis, while
the orthosteric mGlu1 selective antagonist reinforced it. On
the basis of the above considerations, these observations were
predictive of the existence of presynaptic mGlu1 heteroreceptors
on GABAergic nerve endings and of their functional cross-talk
with GABAB autoreceptors.
The efficacy of the orthosteric antagonist in controlling
GABAB-mediated signaling deserves some comments. The lack
of biophase makes unlike the possibility that the mGlu1
antagonist can compete with the endogenous glutamate for the
binding at the presynaptic mGlu1 heteroreceptors on GABAergic
terminals. The possibility, however, exists that, in cortical
synaptosomes, mGlu1 heteroreceptors could have adopted a
constitutive active conformation (De Blasi et al., 2001). This
conformation would assure a productive coupling of the receptor
to the associate G protein and the propagation of the mGlu1-
mediated signaling, despite the absence of the agonist in the
biophase (Musante et al., 2008; Rossi et al., 2013). If this is
the case, the binding of the orthosteric antagonist would force
a conformational change of the receptor protein, interrupting
the coupling of mGlu1 receptors with the G proteins and the
associated intraterminal cascade of events that, we speculate,
could reverberate on the co-localized GABAB receptor protein
(see below).
Interestingly, the genetic deletion of mGlu1 receptor proteins
affects the (±)baclofen-mediated inhibition of GABA exocytosis
in a way that is reminiscent of the impact of mGlu1 antagonist
on the GABAB receptor. In particular, the GABAB-mediated
inhibition of GABA release in cortical nerve endings from
Grm1crv4/crv4 mice is more efficient when compared to WT mice,
but it is largely comparable to that observed in the presence of the
mGlu1 orthosteric antagonist. To note, in cortical synaptosomes
from mutant mice, the expression of the GABAB2 receptor
subunit, i.e., the subunit that dictates the affinity of (±)baclofen
at GABA receptor (Møller et al., 2017 and references therein), is
largely increased when compared to WT mice. This observation
could give the rationale for the changes in the agonist efficacy
observed in mutant mice; further studies are required to correctly
address this point.
To summarize, the observations depicted so far seem best
interpreted by assuming that: (i) mGlu1 heteroreceptors exist
in GABAergic terminals; (ii) they colocalize with GABAB
autoreceptors; (iii) the activation of mGlu1 receptors influences
the GABAB-mediated control of GABA exocytosis; (iv) the
genetic deletion of mGlu1 receptors affect the expression and the
presynaptic release-regulating activity of GABA receptors.
The second result of our study is that the “mGlu1
to GABAB” receptor-receptor cross–talk is not restricted to
GABAergic nerve endings, but rather represents a wide-spread
event that occurs also in other subfamilies of cortical nerve
endings, i.e., the glutamatergic ones. Actually, also in cortical
glutamatergic synaptosomes, the blockade of the presynaptic
mGlu1 autoreceptors reinforced the inhibitory tune exerted by
(±)baclofen at inhibitory presynaptic GABAB heteroreceptors.
In both synaptosomal populations, the “enabling” modulatory
effect exerted by mGlu1 antagonists on GABAB receptors
occurs because of the co-existence of the two receptors on
the same nerve endings, as confirmed by confocal microscopy
showing the overlapping of mGlu1α, GABAB1, and GABAB2
immunostainings in either the VGAT-containing or the
VGLUT1-positive synaptosomal particles. For the sake of
clarity, the mGlu1/GABAB receptor–receptor interaction was
already reported in the literature. In particular, in Purkinje
cells, a GABAB-mediated control of mGlu1-induced signaling
was described, which relied on the physical association of
mGlu1 receptor protein with the GABAB receptor complex.
The assembly of the receptor complex was independent on
G protein-mediated mechanisms, but dependent on external
calcium ions. The final outcome was an increased sensitivity of
mGlu1 receptors to glutamate (Dittman and Regehr, 1996, 1997;
Vigot and Batini, 1997; Tabata et al., 2004). Unfortunately, in the
present case, the role of external calcium in dictating the mGlu1-
GABAB receptor–receptor interaction cannot be investigated,
since the removal of the cation from the superfusion medium
abrogates per se the transmitter exocytosis.
On the basis on the main features of the receptor(s) involved
in the receptor-receptor cross-talk, some speculations on the
molecular event(s) underlying the receptor-receptor cross-talk
can be proposed. It is known that activation of mGlu1 receptors
preferentially leads to the translocation of phospholipase C,
hydrolysis of membrane phosphoinositide and accumulation of
diacylglycerol and calcium ions in the cytosol, which in turn
activate PKC-mediated processes, including GABAB receptor
desensitization. Actually, the phosphorylation of the carboxy
terminus of the GABAB1 subunit assure its dissociation from the
NSF protein and the desensitization of the receptor (Terunuma
et al., 2010). Blockade of the PKC-dependent phosphorylative
processes should therefore be expected to slow GABAB receptor
desensitization, reinforcing its inhibitory control on transmitter
exocytosis, as indeed observed with the selective PKC blocker
GF109209X. On the basis of these considerations, we propose
that the mGlu1-GABAB receptor-receptor cross-talk involves a
PKC-dependent intraterminal phosphorylative pathway which
modulate GABAB receptor desensitization.
CONCLUSION
The results from our study highlight a functional cross-talk
linking excitatory glutamatergic receptors (the mGlu1 receptor
subtype) and inhibitory GABAergic receptor (the GABAB
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complex). We provide evidence that the two receptors colocalize
in both glutamatergic and GABAergic terminals and that the
mGlu1 receptors tune in an antagonist-like manner the efficiency
of the presynaptic release-regulating GABAB receptors.
Synaptic efficiency depends on the equilibrium between
the excitatory and the inhibitory inputs on neurons. mGlu1
antagonist or negative mGlu1 allosteric modulator (NAM)
would reinforce the paracrine effect of GABA at GABAB
heteroreceptors located on glutamatergic nerve endings,
positively tuning the excessive glutamate release that often
characterize central neurological diseases. Concomitantly, mGlu1
antagonist and mGlu1 NAM would reduce GABA exocytosis
from GABAergic terminals, because of the reinforcement of
the inhibitory tone of GABAB autoreceptors at this level.
The “enhancement” of the paracrine GABAergic control of
glutamate release from nerve endings would compensate for
the diminished spillover of GABA at GABAB heteroreceptors
Although further studies are required to define the impact
of “in vivo” administration of mGlu1 ligands on the
presynaptic GABAB-mediated control of both transmitters, our
findings improve the knowledge of the complex homeostatic
mechanisms of control of the excitatory/inhibitory balance
in CNS.
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